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THE ROLE OF FINANCIAL INCENTIVES IN THE TREATMENT OF 
 
 CHILDREN AND ADOLESCENTS INFECTED WITH HUMAN  
 
IMMUNODEFICIENCY VIRUS 
 
ANDREW JAEHYUN LEE 
ABSTRACT 
 Adherence to antiretroviral therapy (ART) is one of the most important issues in 
pediatric patients living with Human Immunodeficiency Virus (HIV).  Combined with 
the fact that young patients face a large array of adherence barriers, interventions that can 
increase adherence are of great interest.  Financial incentives (FIs) are a novel approach 
in pediatric HIV settings, and have not been studied previously in this disease for this age 
group.  Thus, we sought to evaluate the effects FIs had in helping pediatric HIV patients 
achieve and maintain virologic suppression (VS).  Furthermore, a post-incentive survey 
was administered to evaluate the self-perceived effects of FIs.  
 In our study, FIs were not associated with achieving VS among pediatric and 
adolescent patients.  The post-incentive survey has demonstrated many aspects of 
patients’ and guardians’ perceptions of FIs that should be considered in future FI studies.    
First, it was likely that patients who effectively grasped the concept of financial reward 
were most positively influenced by FIs.  Second, the study data suggested that FIs may be 
contra-effective to those patients who report strong emotional responses to negative 
outcomes.  Further and more comprehensive studies are required to fully characterize 
these effects.  
  
  vii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS .................................................................................................. vii 
LIST OF TABLES .............................................................................................................. x 
LIST OF FIGURES .......................................................................................................... xii 
LIST OF ABBREVIATIONS .......................................................................................... xiii 
INTRODUCTION .............................................................................................................. 1 
HIV/AIDS IN CHILDREN............................................................................................. 1 
Burden of HIV/AIDS. ................................................................................................. 1 
HIV in the pediatric population. ................................................................................. 2 
Medication Adherence in HIV. ................................................................................... 3 
Adherence Interventions ................................................................................................. 6 
Financial incentives as an intervention ........................................................................... 8 
Financial incentives in healthcare. .............................................................................. 9 
  viii 
Concerns with financial incentives. .......................................................................... 10 
Specific aims ................................................................................................................. 11 
METHODS ....................................................................................................................... 13 
Overview of study design ............................................................................................. 13 
Study Population ........................................................................................................... 14 
Children’s National Medical Center. ........................................................................ 14 
Financial incentive population. ................................................................................. 15 
Post-incentive survey population. ............................................................................. 15 
Interventions ................................................................................................................. 15 
Financial Incentive Arm. .......................................................................................... 15 
Exit Survey Arm. ...................................................................................................... 17 
Statistical Procedures .................................................................................................... 18 
RESULTS ......................................................................................................................... 20 
Effects of Financial Incentives...................................................................................... 20 
Study Population. ...................................................................................................... 20 
Financial Incentives. ................................................................................................. 21 
Effects of FIs on virologic suppression. ................................................................... 23 
Survey Study ................................................................................................................. 29 
Characteristics of survey respondents. ...................................................................... 29 
Survey results. ........................................................................................................... 31 
Correlations between survey answers and the effects of FIs. ................................... 41 
DISCUSSION ................................................................................................................... 43 
  ix 
Financial Incentive Arm ............................................................................................... 43 
Post-incentive patient/ guardian survey ........................................................................ 47 
Self-perceived effects of FIs. .................................................................................... 47 
Satisfaction with participation in the FI study. ......................................................... 50 
Personal responsibility and barriers to adherence. .................................................... 53 
Conclusions and Future Directions ............................................................................... 56 
LIST OF JOURNAL ABBREVIATIONS........................................................................ 57 
REFERENCES ................................................................................................................. 60 
VITA ................................................................................................................................. 76 
 
  
  x 
LIST OF TABLES 
 
 
Table Title Page 
1 The eligibility and distribution of the FIs 22 
2 The effects of FIs in all patients in the TLC-Plus FI study 
at 12 months, 18 months, 24 months, and IC of the study 
24 
3 Baseline VL characteristics including age, gender, and 
state of residence 
24 
4 Total number of patients on TLC-Plus FI study stratified 
by age 
25 
5 Results of the Pearson’s chi-squared tests evaluating the 
relationship between FIs and VLs in ITE (0 to 5 years 
old), childhood (6 to 13 years old), and youth (above 13 
years old) cohorts 
26 
6 Sample number, contingency table, and results of the 
statistical analysis of the effects of FIs on VL in patients 
with more than 0 cards, but less than 100% of eligible 
cards 
27 
7 Total number of survey respondents by patient, guardian, 
and family.  Mean ages and proportions of patients in each 
age cohort of families participating in the survey 
30 
  xi 
8 Selected responses to survey questions 36 to 39 
9 Survey responses that were significantly correlated to 
changes in VL throughout the FI study 
40 
  
  xii 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Rates of virologic suppression at 12 months, 18 months, 
and 24 months in the TLC-Plus FI study compared to 
baseline VL laboratory values 
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  xiii 
LIST OF ABBREVIATIONS 
AIDS 
  
Acquired Immuno Deficiency Syndrome 
    
ART 
  
Anti-Retroviral Therapy 
    
CD4+ 
  
Cluster of Differentiation 4 positive 
    
CDC 
  
Center for Disease Control 
    
CL 
  
Confidence Limit 
    
CNMC 
  
Children's National Medical Center 
    
DC 
  
District of Columbia 
    
DNQ 
  
Did not Qualify for a FI 
    
DNR 
  
Did Not Respond 
    
DOH 
  
Department of Health 
    
DOT 
  
Directly Observed Therapy 
    
FI 
  
Financial Incentive 
    
HAART 
  
Highly Active Anti-Retroviral Therapy 
    
HIV 
  
Human Immunodeficiency Virus 
    
HPTN 
  
HIV Prevention Trials Network 
    
IC 
  
Individual Completion 
    
ITE 
  
Infants, toddlers, and early children 
    
MD 
  
Maryland 
    
mL 
  
Milliliter 
    
  xiv 
N/A 
  
Not Applicable 
    
NC 
  
North Carolina 
    
OR 
  
Odds Ratio 
    
PFP 
  
Patients whose families participated in the survey 
    
PK   Pharmacokinetics 
    
PMTCT   Prevention of Mother to Child Transmission 
    
PoG 
  
Patients of guardians who submitted a survey 
    
PR 
  
Patient Response 
    
SIS 
  
Special Immunology Services 
    
TLC-Plus 
  
Treatment and Linkage to Care- Plus 
    
TR 
  
Total Response 
    
UNAIDS 
  
Joint United Nations Program on HIV/AIDS 
    
UNICEF 
  
United Nations International Children's Emergency  
 
 
  
Fund 
 
VA 
  
Virginia 
    
VL 
  
Viral Load 
    
VS   Viral Suppression 
    
 
 1 
 
INTRODUCTION 
 
HIV/AIDS IN CHILDREN 
 
Burden of HIV/AIDS.  Since early 1990, the HIV pandemic has touched every 
corner of the world, and remains a critical healthcare issue today.  Part of what makes this 
pandemic so robust is the complexity of the disease, nature of the virus, and treatment 
target.  Internationally, it was estimated that 35.3 million people were living with HIV in 
20121.  Of those, children represent 3.3 million.  Though there were 260,000 new 
pediatric infections in 2012, this represents a drastic improvement from the recent past.  
This improvement is largely due to the strong emphasis on the prevention of mother to 
child transmission (PMTCT) in developed nations.  This emphasis has included 
interventions such as early recognition of HIV infected women through routine testing, 
the provision of antiretroviral medication to pregnant women and infants, delivery by 
elective cesarean section, and others2.  Furthermore, pediatric HIV remains an important 
issue as children with HIV were only receiving about half the treatment coverage of 
adults in 20121 
Within the United States, there were 1.1 million people living with HIV/AIDS by 
the end of 2010.  Similarly, there were 10,834 children living with HIV in 2009, with 217 
new pediatric infections that year3.  Washington D.C. is a particularly unique area in 
terms of HIV, because it is one of the most affected areas in the United States.  Out of all 
U.S. states and territories, Washington D.C. has the highest rate of AIDS diagnoses, HIV 
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infections, and deaths due to AIDS4.  Currently, 2.7% of Washington D.C.’s population is 
living with HIV-- almost 3 times more than the threshold for a generalized epidemic5.  
 
HIV in the pediatric population.  Children living with HIV represent an important 
population of those affected by HIV, due to issues unique to that age group.  Even, mode 
of transmission is unique in children, as almost all children living with HIV are infected 
vertically (from their mother, perinatally)6. 
Though children with HIV may be viewed as one group, it is important to 
recognize that developmental stage stratifies children living with HIV into the loose 
groups —infants, toddlers, and young or pre-school aged children (0 to 5 years of age, 
henceforth collectively referred to as ITE), school aged children (5 to 13 years of age), 
and adolescents or youth (13 to adulthood).  Furthermore, each can be viewed as a unique 
group with unique challenges.  Younger children, in particular, generally require more 
aggressive approaches to the invitation of antiretroviral therapy (ART), since the 
progression of the disease has been reported to be faster in this age cohort7.  Younger 
patients also have different pharmacokinetics (PK) and toxicities associated with ART.   
Childhood is also a period of immense psychosocial growth.  Therefore, it is no 
surprise that children with HIV also have unique psychosocial issues8.  For example, due 
to HIV related encephalopathy, pediatric patients with HIV have a significantly higher 
risk of developing cognitive, motor, and behavioral deficits.  A variety of emotional 
issues have also been associated with pediatric HIV infection, with depression and 
anxiety being the two most common conditions observed in children.  It has also been 
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suggested that increased stress from HIV-related issues negatively influence the 
development of normal coping skills, which in turn manifests in disturbed emotional 
states8.  Other important psychosocial issues unique to childhood are centered on the HIV 
status of a caregiver; disclosure of HIV diagnosis; and its effects and considerations 
during sexual development. 
Overall, all of these factors contribute to the complexity of pediatric HIV 
infection and, pose serious challenges to adherence to ART in children. 
 
Medication Adherence in HIV.  The biology of HIV creates unique challenges to 
its treatment and finding a cure.  HIV has the capacity to effectively evade multiple 
protective barriers of the immune system9,10, reducing the body’s ability to combat the 
disease.  HIV also develops resistances to ARV drugs, due to its low replication time, low 
fidelity of reverse transcriptase, and ease of recombination with other strains11.  Despite 
these challenges, ART has been an extremely effective tool against HIV.  Steady use of 
combination ART leads to increased CD4+ counts, less development of viral resistance, 
and suppressed viral replication resulting in low or undetectable HIV viral loads (VLs)12.  
As a result, adhering to ART prevents progression of HIV infection into AIDS, and 
dramatically decreases AIDS associated morbidity and mortality13–16. 
Poor adherence is one of the most crucial issues in HIV17–20.  Despite the high 
effectiveness of ART, it is estimated that only 19% of HIV infected people in the United 
States have achieved steady VS21.  Though adherence has improved over time, primarily 
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due to decreases in ART associated toxicities, a significant proportion of HIV-infected 
people continue to report suboptimal ART adherence22–25. 
Studies have shown that high levels of medication adherence—about 95% of 
prescribed doses—need to be in place for ART to reach maximal efficacy12.  For ART, 
however, multiple barriers to adherence exist, and include but are not limited to, lack of 
social support, HIV associated stigma, treatment fatigue, cost, adverse events, metabolic 
complications, and psychological issues such as anxiety and depression, and chronic 
pain26–30. 
ART adherence is especially important in the pediatric setting.  It is more 
complex than in the adult setting as guardian, societal, and other external factors need to 
be considered in addition to the patient31.  Adolescence is also one of the most 
notoriously difficult periods of poor adherence32, which has resulted in it being one of the 
best predictors of suboptimal ART adherence30.  In fact, it has been estimated that at least 
50% of younger patients have suboptimal adherence12,25,33,34, with the lowest reported 
rate of being completely adherent to medication at 20%  in adolescents and young 
adults35.   
Poor adherence has also been shown to be correlated with poor biologic outcomes 
in children, adolescents, and young adults36.  Shockingly, only 6% of all HIV infected 
youth in the United States were estimated to be virally suppressed, suggesting that poor 
ART adherence is an important issue to address37.  Even within HIV infected youth 
seeking care, they are frequently reported to not be virally suppressed34,37.  This is 
especially relevant from a public health perspective as VS is important to reduce 
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transmission of HIV and the development of resistances.  Thus, improving ART 
adherence in the pediatric setting is a significant challenge.   
Poor adherence is a difficult challenge in pediatric HIV patients, due to the 
multitude of barriers, complex considerations, and the dynamic and inconsistent nature of 
barriers in these patients.  Young HIV patients are also susceptible to additional barriers 
to adherence.  In ITE and school-aged child patients barriers commonly include poor 
communication skills, limited cooperation by the child, the caregiver’s guilt and 
stress29,30, premature assignment of responsibility, and family environment 38.  In 
adolescents, who tend to take on more responsibility in their care, barriers to adherence 
are even more complicated.  Due to the number of barriers identified, they are often 
grouped in terms of patient issues, medication issues, and structural issues17.  Commonly 
reported barriers in this age group include forgetting, lifestyle choices, stressful life 
events, lack of insurance, family related issues, housing instability, and transportation 
issues29,39.  In light of the fact that the number of barriers to adherence reported strongly 
correlates with percentage of missed doses in HIV-infected youth40, it is no surprise that 
adolescence represents one of the most difficult periods of adherence. 
Though many barriers to adherence have been identified in youth infected with 
HIV, the fact that barriers are not consistently present in all patients has been an added 
challenge.  Moreover, the rapid changes associated with development makes these 
barriers highly dynamic compared to the more static barriers of adulthood, which can be 
effectively managed with systematic preparation41.  Thus, it can be seen that adherence in 
pediatric HIV patients is a difficult and critically important issue. 
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Adherence Interventions 
Improving medication adherence is an important and difficult task.  Without 
accounting for increases in healthcare spending, lost wages, burden on society, and other 
peripheral effects42, non-adherence costs the United States approximately $100 billion in 
hospital visits alone29.  Currently, the WHO estimates that less than 50% of patients with 
chronic conditions are adherent to their prescribed regimens43.  Adherence barriers are 
particularly significant in chronic diseases compared to acute health conditions.  This is 
due to the fact that patients tend to be less adherent over time44, and have increased 
barriers to adherence associated with long-term therapies45. 
Many studies have investigated methods for improving adherence in HIV-infected 
patients.  However, it is important to note that interventions are differentially effective in 
different age groups.  In adults living with HIV, pharmacist led individualized 
interventions, cognitive/behavioral educational interventions, and cue-dosing training 
with monetary reinforcements are some of the most effective individual interventions29.  
Multicomponent ART adherence interventions have also been very successful in adults46–
49.  In fact, 9 of 11 multicomponent studies in adults effectively improved adherence over 
the standard of care.  The most effective multicomponent interventions combined patient 
education, adherence tools, and a system to address common barriers to ART 
adherence41.  Despite the effectiveness of these interventions, they tend to be costly and 
difficult to maintain on long-term bases. 
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In HIV-infected children and youth, most common interventions have included 
educational activities, training, behavior modification, technical tools to assist with 
adherence, referrals to social and mental health services, and home nursing visits.  
Unfortunately, these interventions as not universally effective, as each presents unique 
challenges to consider.  Among youth with HIV-infections, directly observed therapy 
(DOT), where providers directly administer the medication, has been one of the most 
successful interventions50–52.  However, practical application of DOT is limited because 
of its high cost.  Another intervention, reducing pill burden, has been shown to lead to 
higher adherence in treatment-naive adolescent patients53.  However, this intervention is 
not effective for patients struggling with pill size and swallowing barriers.  Educational 
approaches have also been studied among adolescents, but have provided inconclusive 
results54,55.  Overall, it can be seen that more robust adherence interventions in the 
pediatric HIV setting are urgently needed35. 
Interestingly, a promising adherence intervention study was conducted in youth 
with HIV infections56.  This adherence intervention gave cell phones and plans to youth 
living with HIV for their ART dosing reminders.  While this effective intervention was 
intended to provide monitoring to reduce forgetfulness, it could also be construed as an 
incentive for adherence.  Along these lines, it is possible that incentives can be an 
effective adherence intervention in young HIV patients, and are worth further study.  
Financial incentives (FIs), a type of incentive intervention, thus have a potential 
application in the management of the pediatric and adolescent HIV infections. 
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Financial incentives as an intervention 
FIs represent the use of money to influence behavior.  They can be positive, like a 
gift card reward, or negative, like a fine for breaking a rule.  FIs have been investigated as 
a means to influence both patient and healthcare provider behavior44.  They are also of 
great interest for adherence management, since they represent a potential tool to decrease 
healthcare costs and improve health outcomes57.  In fact, a study by the American 
College of Physicians found that FIs help restrain medical costs in several foreign 
countries58. 
The basics of FIs are rooted in behavioral economics.  This branch of economics 
recognizes that people do not always exhibit optimal decision making, and are more 
driven by short-term outcomes and larger life events.  Behavioral economics takes 
advantages of these things to drive optimal behavior that can ultimately be predicted by 
classical economics59,60.   
In order to take advantage of quirks in reasoning61, behavioral economics often 
dictate that FIs are applied in 3 key directions62.  First, in order to take advantage of time 
bias, a relatively frequent reward schedule is used.  Second, in order to emphasize goals 
and benefits of the incentive, FIs are made as salient as possible.  For example, FIs are 
rarely grouped with a paycheck, as this may dilute the goals of a program.  Finally, FIs 
account for psychological constructs like anticipated regret, over weighing of 
probabilities and loss aversion.  A lottery incentive structure is a good example of this, as 
people often believe that they can beat the odds.  Importantly, as long as these conditions 
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are met, large amount of compensation is not required62.  This makes FIs an attractive 
tool from a cost-benefit perspective. 
 
Financial incentives in healthcare.  FIs have been shown to successfully modify 
health related behavior in a variety of environments and medical conditions.  Perhaps the 
two most famous examples are the role of FIs in smoking cessation63 and weight loss64,65.  
In the smoking cessation study, it was reported that FIs were responsible for a 10% 
improvement in smoking cessation within the first 6 months of participation, which 
importantly, lasted after the incentive period.  Conversely, the differences between 
incentive and control groups in the weight loss studies were lost after the incentive 
periods. 
FIs have also been applied as a medication adherence intervention.  For example, 
they have successfully helped patients at risk for thromboembolism adhere to their 
warfarin regimens66.  They have also been effective in myocardial infarction prophylactic 
medication, antipsychotic medication, and drug addiction medication adherence 
interventions67–69.  When combined with coaching, FIs also successfully improved 
adherence to hypertension medication despite increased complexity and medication 
changes70.  Based on patient claim data, this program actually allowed a decrease in 
medical costs.  FIs were less effective than peer mentoring at improving adherence to the 
therapy for diabetes71.  However, when combined with peer mentoring and coaching, FIs 
were able to improve medication adherence in patients with diabetes70.  These data allow 
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us to consider FIs as a potentially effective component of adherence interventions for 
ART. 
FIs have also been effective in the pediatric setting with helping guardians take 
care of their children.  For example, FIs significantly helped expectant mothers quit 
smoking72.  FIs also helped mothers keep their children up to date with well-child visits73 
and compliant with Children’s Health Insurance Program guidelines74.  Thus, it can be 
seen that FIs can effectively help guardians alter their behavior for their children. 
Finally, FIs have also been studied in HIV/AIDS patients.  The majority of HIV-
related studies have been conducted in adults with a history of drug abuse.  While FIs 
helped these patients be more adherent to their ART regimens75–77, the observed 
improvements in adherence were frequently lost following the end of FIs, and often there 
were no improvements in biologic outcomes of HIV disease such as HIV VLs and CD4+ 
counts. 
 
Concerns with financial incentives.  From an ethical standpoint, one of the biggest 
dangers of FIs is related to their potential to exacerbate social inequalities78.  A good 
example of this would be restructuring co-pays to improve adherence.  Under this 
structure, the sub-population most sensitive to changes in co-pay would likely be the least 
in need of improved adherence.  Though overall adherence may improve, little to no 
change may be seen in the sub-population most in need of this intervention62.   
In fact, this concern was observed in two of the aforementioned smoking cessation 
studies.  In the first study, the authors noted a group of employees who were uniquely 
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unaffected by the incentives.  The authors concluded that these participants were most 
likely not interested in quitting63.  In the other study, the authors reported that the mothers 
who were the poorest, youngest, and struggling the most with quitting were unaffected by 
the FIs72. 
Despite the success of the aforementioned studies, many incentive interventions 
did not result in sustained adherence, as FIs are also often most effective in helping 
patients complete short courses of medication68.  In fact, it has been said that FIs may be 
best utilized for short term adherence issues and acute patients29,79.  Even in the 
aforementioned ART adherence interventions and weight loss studies with successful 
outcomes, improvements in adherence were not sustained for the long term.  Thus, it can 
be seen that the role of FIs in managing chronic adherence to ART, where it is needed the 
most, needs to be determined. 
     
Specific aims 
As previously mentioned, adherence to antiretroviral therapy is one of the most 
important issues in pediatric HIV.  Because of this, there is a continuous need for more 
effective adherence interventions, and a better understanding of the issues influencing 
adherence in pediatric HIV patients.  While many interventions have been studied to date, 
FIs represent a novel approach in the pediatric HIV setting.  Based on their effects in 
adults, FIs may be an effective potential tool to help pediatric HIV patients adhere to their 
antiretroviral therapy. 
This study was designed to address the following 2 aims: 
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1.  First, we evaluated the effects of FIs on VS.  This is defined as a VL of ≤400 
copies/mL, and is used as an indirect measurement of adherence.  The primary outcome 
of this aim was the probability of having a VL below the threshold value after 12-months 
of receiving FIs for low VLs. 
2.  Second, we evaluated the patients’ and guardians’ self-perceived experiences 
with FIs, with a particular focus on the self-perceived effects of the FIs on adherence and 
VS.  These data will also allow us to compare the actual relationship of the FIs to VS 
with the self-perceived effects on adherence.  
 13 
 
METHODS 
 
Overview of study design  
This study was a component of a larger national site-randomized study that 
evaluated the feasibility of an enhanced community-level test, link to care, plus treatment 
strategy in the United States, also known as “Test and Link to Care, Plus” (TLC-Plus)80.  
TLC-Plus is a study of the HIV Prevention Trials Network (HPTN), and includes 5 major 
research components.  This study was part of the VS component of the TLC-Plus study.  
The aim of the VS component was to compare a FI intervention with the standard of care 
for achieving and maintaining suppressed VLs in HIV-positive patients in care, managed 
under the prevailing guidelines for the initiation of ART. 
Within the prospective cohort of the pediatric and adolescent HIV-infected 
patients who participated in the TLC-Plus study at CNMC, this sub-study evaluated the 
effects of FIs on virologic outcomes in children and adolescents with perinatally acquired 
HIV.  In addition to the assessment of the relationship between the FIs and virologic 
outcomes, a site-specific cross-sectional ancillary study was conducted within 6 months 
of the completion of the FIs among caregivers of children and adolescents and adolescent 
patients ≥12 years old.  This study aimed to investigate self-perceived experiences with 
FIs and self-reported effects of the FIs on VS among caregivers of children and 
adolescents and adolescent patients (≥12 years old).  Final analysis compared the 
observed effect of FIs on VS with the caregiver/adolescent patient paired self-reported 
perceptions of the effects of FIs on adherence and virologic outcomes. 
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Study Population 
Children’s National Medical Center.  Patients receiving care at the Special 
Immunology Services (SIS) Program, which provides care to primarily perinatally HIV-
infected children and adolescents in the Washington D.C. metropolitan area, were eligible 
for study enrollment.  Pediatric and adolescent patients are seen at the SIS for routine 
medical care every 3 months, and more frequently when indicated.  During each visit 
laboratory results and medication regimens are reviewed with the patients and guardians.  
Both are also provided with detailed verbal and written directions on their ART regimens.  
Patients also have access to Psychosocial Support Services, which provides HIV peer 
support groups to adolescent and young adult clients of the SIS.  This program, which is 
funded by the Ryan White HIV/AIDS program, helps young people living with HIV cope 
with their HIV diagnosis, adhere to complex treatment regimens, and adjust socially and 
emotionally to living with HIV.  Support services, including adherence services, are also 
available to guardians of patients.  Various adherence intervention options are also 
provided by the clinic staff and Ryan White supported personnel.   
The gender ratio of the patients at CNMC is approximately 1:1, and the majority 
of the 188 patients in care are represented by Black children and youth from metropolitan 
D.C., which includes suburban Maryland and Virginia.  Both the TLC-Plus incentive and 
ancillary survey study were reviewed and approved by CNMC’s Institutional Review 
Board. 
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Financial incentive population.  The FI population was comprised of all patients 
in care who agreed to participate in the TLC-Plus study.  Eligibility criteria for the FI arm 
included an HIV positive diagnosis and a current prescription for ART under the 
prevailing guidelines.  Patients were required to have a VL measurement 3 to 9 months 
prior to the first VL measurement that qualified for a FI. 
Once eligible patients were identified, they were approached for enrollment by 
clinic or research staff.  Disclosed patients only and guardians of all patients were 
provided with the study information sheets and the study was explained to them verbally.  
Patients could refuse study participation.  A total of 167 patients were eligible to 
participate in the FI study.  The reasons for refusal were recorded anonymously by the 
study staff.  The study period, during which patients were eligible to qualify for a FI, 
lasted 24 months, from April, 2011 through April, 2013, and subjects were enrolled and 
continued study participation throughout this period.  The last FI was distributed in June, 
2013.   
Post-incentive survey population.  Exit study surveys were conducted by clinic 
and research staff with disclosed patients ≥12 years of age and all available guardians 
within 6 months after receiving their last FI.  A total of 146 families were eligible to 
participate in the exit survey.    
 
Interventions 
Financial Incentive Arm.  Patients in the FI study received a $70 FI if their 
quarterly HIV VLs were ≤400 copies/mL.  VL measurements which were ≥3 months 
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from the last VL that qualified for a FI were defined as eligible VL measurements.  
Qualifying VLs were defined as an eligible VL ≤400 copies/mL, which in turn allowed a 
patient to receive a FI.  If a patient had a qualifying VL measurement at CNMC before 
the start of the study, that patient received a FI at the start of the study.  The maximum 
number of FIs the patient could qualify for was 9 in a 24 month span.  However, due to 
differences in how frequently patients visited CNMC, patients were often eligible for less 
than 9 FIs during a 24 month span.  If a patient had an HIV VL >400 copies/mL at a 
quarterly visit, and was scheduled to come back to CNMC before his/her next quarterly 
visit for a medical reason (psychology appointment, routine checkup, adherence follow 
up, etc.), the patient was given the opportunity to re-qualify for the FI he/she did not 
qualify for during the previous visit.   
Research assistants distributed FIs after confirming that VLs for that quarterly 
visit were ≤400 copies/mL.  Research assistants distributed the FIs at the patient’s next 
quarterly visit.  However, patients were also given the option to pick up their FIs before 
those visits.  The FIs were handed to the patients or caregivers per family discretion.  If 
adolescent patients were seen without their caregivers, they received the FI.  Adolescents 
(≥12 years of age) or guardians of patients of all ages could sign to confirm receipt of the 
voucher. Patients and the guardians of the patients who had VL >400 copies/mL were 
notified of their laboratory results, and informed that the FIs would not be distributed.  
This was done to increase the salience of the FIs, take advantage of loss regret, and 
increase transparency in the study. 
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Exit Survey Arm.  The study’s exit survey was administered within 6 months of 
receipt of the last FI to better understand the self-perceived effects of FIs on ART 
adherence and laboratory values.  The study also sought to evaluate satisfaction with 
study participation, role of the patient in the distribution of the FIs, use of the FIs, and 
satisfaction with FI amount. 
Surveys were formatted to make them as similar as possible between guardian and 
patient versions.  Due to issues with comprehension and disclosure status, surveys were 
only administered to adolescent patients ≥12 years of age who were disclosed of their 
HIV status.  The focus of the guardian survey was the perceived role of FIs in their 
children’s adherence to their ART regimens.  The focus of the patient survey was the 
patients’ perceptions of FIs in their adherence to their ART regimen.  Accordingly, 
questionnaires obtained data on the self-perceived effectiveness of FIs in supporting 
adherence, utilization of the FIs, the roles of the caregiver and patient in distributing and 
using the FIs, and the perceived role of FIs in long term care for pediatric and adolescent 
conditions.  Questions used the Likert Scale for answers, with two main scales used.  The 
scale provided the following possible answers: strongly agree, agree, neutral, disagree, 
and strongly disagree.  Choices available to describe feelings about receiving the FIs 
were: extremely satisfied, very satisfied, satisfied, somewhat satisfied, and unsatisfied.  
Surveys were administered from May, 2013 to November, 2013.  This time-frame 
was restricted to minimize the effects of memory bias.  Patients and guardians who were 
unable to complete surveys due to difficulty remembering or unable to participate in the 
survey within the 6 month window were excluded. 
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Statistical Procedures 
Patient demographics, results of the HIV RNA VL measurement, distribution of 
the FIs, and questionnaire responses were all entered into an electronic study database.  
All statistical analysis was performed using SAS 9.3.2014 (Cary, NC).  Descriptive 
statistics were calculated for all continuous variables, and frequency tables were 
generated for all categorical variables when appropriate.  Associations between 
population variables were quantified with multivariate logistic or linear regressions when 
appropriate.  P-values <0.05 were considered significant for all analyses. 
The primary outcome measure of the FI arm is the probability of VS, defined as a 
VL ≤400 copies/mL, after 12 months, 18 months, and 24 months of participation in the FI 
arm.  The probability of VS at individual completion of the study was used as a 
secondary outcome measure.  Odds ratios were calculated to evaluate the relationship 
between FIs and VL.  The effects of FIs on VL were also evaluated in terms of gender, 
age, place of residence (PR), and various general FI characteristics.  These FI 
characteristics included: the number of cards eligible for (the number of cards considered 
for), number of FIs qualified for (the number of cards families could receive), number of 
FIs received, when FIs were picked up, and who signed for receipt of the FI (guardian or 
patient).  Due to inherent age related differences in development and caretaker 
involvement, the FI study population was stratified to reflect these differences for the 
final analysis into the following 3 groups: infants/toddlers/early childhood (ITE) (0 to 5 
years old), school aged children (5 to 13 years old), and youth (above 13 years old).  
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Multinomial logistic regressions and odds ratios were also calculated to compare the 
relationships between specific responses to survey questions, adherence, virologic 
suppression, and FIs.  
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RESULTS 
 
Effects of Financial Incentives 
 Study Population.  From April, 2011 to April, 2013 188 patients received care at 
the SIS Program at CNMC.  Of these patients, 166 patients were eligible for participation 
in the TLC-Plus FI study.  Overall, 161 of the 166 eligible patients were approached to 
participate in the study.  There were 4 patients that met the eligibility requirements for 
participation in the FI study, but were not approached because they moved to a different 
clinic before enrollment in the study.  The last patient was not approached due to being 
on a holding regimen, which prevented the patient from having a VL ≤400 copies/mL.  
Overall, 156 of the 161 approached patients verbally agreed to participate in the TLC-
Plus study.  Five patients declined participation in this study and the initial FI: 3 were due 
to patient’s refusal; 1 was due to religious beliefs and cultural preferences prohibiting the 
acceptance of monetary gifts; and 1 was due to the discontinuation of ART at the start of 
the study. 
The mean age of patients at the start of the incentive study was 11.69 years old (2 
to 18 years old in range).  When stratified by age, the patients were divided as following:  
ITE (0 to 5 years old, n= 16, 10%), school aged children (6 to 13 years old, n= 72, 46%), 
and youth (>13 years old, n= 68, 44%).  In terms of gender, the incentive population was 
roughly equally distributed between males (n=75, 48%) and females (n=81, 52%).  The 
mean ages of the male and female patients were 13 and 11 years old, respectively.  
Interestingly, there was a significant association between gender and age.  A multivariate 
 21 
 
regression comparing age to gender showed that a 1 year increase in age resulted in a 
12% reduction in the odds of being female (OR: 0.888; 95% CL: 0.824- 0.957).  Patients 
in the study were primarily from Washington D.C. (n= 57, 37%) and Maryland (n=73, 
47%).  Only 16% of patients in the study were from the Virginia area (n= 25). 
 
 Financial Incentives.  A total of 130 out of 156 patients received at least one $70 
FI during the TLC-Plus study, which represents 83% of patients enrolled.  In total, there 
were 860 VL results that met the criteria to be considered for a FI (representing “eligible 
VLs,” see methods for a more detailed explanation and comparison with a “qualifying 
VL”), which were spread between 156 patients (Table 1).  Patients were eligible for a 
mean of 5.51 FIs, qualified for a mean of 3.88 FIs, and received a mean of 3.88 FIs.  The 
majority of patients (n= 89, 68%) consistently elected to pick up their cards at their next 
appointment or later, while one-third of patients (n=41) primarily picked up their cards 
before their next appointment (Table 1). 
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Table 1: The eligibility and distribution of the FIs. 
Patients Receiving Cards Total Eligible Patients Percent Receiving Cards 
130 157 0.83 
Cards Eligible for: Cards Qualified for (%): Total Cards Accepted (%): 
860 621 (72%) 606 (98%) 
Mean Cards Eligible (s.d.) Mean Cards Qualified for (s.d.) Mean Cards Accepted (s.d.): 
5.51 (±1.90) 3.98 (±2.77) 3.88 (±2.76) 
Cards Signed for: 
% Patient (n): % Guardian (n): % Both Equally (n) 
47%  (61) 48%  (62) 5%  (7) 
% Picked Up Cards: 
% Early than next 
appointment (n): % At appointment or later (n): N/A 
32% (41) 68%  (89) N/A 
 
A multivariate logistic regression analysis was conducted to evaluate the 
relationship between age group and general FI properties, including eligibility, 
qualification, and pick up practice as outline in Table 1.  As expected, age was 
significantly related to who signed for receipt of the FIs.  Transitioning to an older age 
group made it 58.5% less likely that the guardian signed for the FI (OR: 0.415; CL: 
0.258- 0.557).  All other FI characteristics were independent of the patient’s age (data not 
shown). 
 The mean time during which patients were eligible to receive a FI was 17.48 
months, while participation in the FI process ranged from less than 1 month to 24 months 
between the enrolled subjects by the end of the study.  Of the 156 patients enrolled in the 
FI study, 136 (87%) were eligible for FIs for 12 months, 109 (70%) for 18 months, and 
33 (21%) for all 24 months. 
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 Effects of FIs on virologic suppression.  At baseline, 107 (69%) of the 156 
patients participating in the FI study were virally suppressed (≤400 copies/mL) (Figure 
1).  After 24 months of FI eligibility, there was a 10% increase in the proportion of 
patients with virologic suppression, though this change was statistically insignificant. 
 
Figure 1: Rates of virologic suppression at 12 months, 18 months, and 24 months in the TLC-Plus FI study 
compared to baseline VL laboratory values. 
 
 
Pearson’s chi-squared analyses comparing the participation in the FI study and its 
effects on VLs did not demonstrate a significant association between the proportion of 
patients with VS at any of the time points (Table 2).  Importantly, the chi-squared value 
comparing VLs at each individual endpoint to baseline was 0, which reflects the fact that 
overall population numbers did not change between these 2 time points. 
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Table 2: The effects of FIs in all patients in the TLC-Plus FI study at 12 months, 18 months, 24 months, 
and IC of the study.  Pearson’s chi-squared analysis was used to compare the proportion of patient VLs at 
these time points to VLs at baseline. 
FI vs. Time Chi-Squared Value p-value OR 95% CL 
12 Months 0.094 0.802 0.926 0.550 1.562 
18 Months 0.015 0.904 0.968 0.555 1.699 
24 Months 1.359 0.298 1.701 0.659 4.953 
IC 0.000 1.000 1.000 0.603 1.659 
 
 Since no significant differences in overall VL due to participation in the FI study 
were detected, total numbers were analyzed by subpopulations to evaluate the effect of 
age, gender, and PR on the rates of VL.  For the effects of age, mean VLs increased with 
age (Table 3).  VLs in males were approximately 5.2 times larger than VLs in females.  
When correcting for age, however, this difference was statistically insignificant.  Finally, 
the patients from Washington D.C. had the highest mean VL followed by the patients 
from Maryland and Virginia.  Importantly, a multivariate logistic regression between 
these variables—age, gender, location, and baseline VL—did not yield any significant 
association. 
 
Table 3:  Baseline VL characteristics including age, gender, and PR. 
Avg. VL by 
Category Age Gender 
Group 0 to 5 y.o. 6 to 13 y.o. >13 y.o. Female Male 
Mean HIV RNA 
VL (copies/mL) 
(±s.d.) 
6508.8 
(±13969.1) 
18027.3 
(±54859.5) 
102292.7 
(±393474.5) 
17688.4 
(±61064.0) 
92336.6 
(±374205.5) 
N/A Location 
  Group DC MD VA 
  Mean HIV RNA 
VL (copies/mL) 
(±s.d.) 
108357.4 
(±424712.7) 
16070.2 
(±47653.8) 
39165.8 
(±117819.2) 
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 The relationship between effects of FIs on VL and age were analyzed and the data 
are presented in Table 4.  It is important to note that the sample sizes at 18 and 24 months 
for the ITE cohort were too small to run a Pearson’s chi-squared test.  The sample size for 
children at 24 months of participation on FIs was also too small to run a chi-squared 
analysis.  Fisher’s exact tests were performed for these cohorts and were found not to be 
statistically significant (results not shown).  Results of the Pearson’s chi-squared tests are 
shown in Table 5.  In all of the age groups listed, FIs did not significantly influence VL 
values at any of the time points observed.  
 
Table 4: Total number of patients on TLC-Plus FI study stratified by age.  Total sample numbers and 
contingency tables used to evaluate the effects of FIs on VL laboratory results in different age groups.  
Samples with insufficient numbers to run a Pearson’s chi-squared test are in red text. 
0 to 5 y.o. Baseline 12 Months 18 Months 24 Months IC 
≤400 c/mL 10 12 9 4 12 
>400 c/mL 6 4 2 0 4 
Totals 16 16 11 4 16 
      
6 to 13 y.o. Baseline 12 Months 18 Months 24 Months IC 
≤400 c/mL 51 40 34 13 51 
>400 c/mL 21 20 13 2 21 
Totals 72 60 47 15 72 
      
>13 y.o. Baseline 12 Months 18 Months 24 Months IC 
≤400 c/mL 46 39 31 9 44 
>400 c/mL 22 21 20 5 24 
Totals 68 60 51 14 68 
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Table 5: Results of the Pearson’s chi-squared tests evaluating the relationship between FIs and VLs in ITE 
(0 to 5 years old), childhood (6 to 13 years old), and youth (above 13 years old) cohorts.  Values in grey 
text represent samples with an insufficient sample size to run an accurate chi-squared test. 
0 to 5 y.o. χ2 p-value OR 95% CL 
12 Months 0.5818 0.7043 1.8 0.3944 8.2151 
18 Months 0.2679 0.4048 2.7 0.4304 16.9376 
24 Months 2.1429 0.2675 Infty 0.3993 Infty 
Completion 0.5818 0.7043 1.8 0.3944 8.2151 
      
6 to 13 y.o. χ2 p-value OR 95% CL 
12 Months 0.2653 0.7062 0.8235 0.3932 1.7246 
18 Months 0.0316 0.8588 1.0769 0.476 2.4367 
24 Months 1.6002 0.3352 2.6765 0.5551 12.9041 
Completion 0 1 1 0.4874 2.0517 
      
>13 y.o. χ2 p-value OR 95% CL 
12 Months 0.1001 0.8516 0.8882 0.4261 1.8515 
18 Months 0.601 0.5612 0.7413 0.3475 1.5815 
24 Months 0.0594 0.8075 0.8609 0.2579 2.874 
Completion 0.1314 0.8563 0.8768 0.4307 1.7852 
 
 
 To test whether FIs had a gender specific effect on VLs over time, the relationship 
between FIs and VL were analyzed separately in females and males, and no significant 
association was found by gender as well (results not reported).   
 The effects of FIs on VL were also analyzed stratified by PR and did not 
demonstrate any significant association with a specific area at any of the time points 
observed (results not reported).   
When evaluating patient identifiers for receiving FIs, it appeared that the patients 
could be divided into three cohorts: those who had consistently low VLs, those who had 
consistently high VLs, and those whose VLs fluctuated between low and high throughout 
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the course of the FI study.  It is possible that the patients who consistently had the same 
results wouldn’t be influenced by FIs, because they couldn’t improve their perfect ART 
adherence (patients with consistently low VLs) or their barriers to adherence  could not 
be addressed by FIs (patients with consistently high VLs).  In our analysis we wanted to 
focus on those patients whose VLs changed throughout the course of the study.   
In order to identify this population of patients, FIs were used as an indicator of 
fluctuations in VLs.  Thus, patients who received more than 0 cards, but received less 
than 100% of the cards they were eligible for were identified.  The effects of FIs on VLs 
at 12 months, 18 months, 24 months, and IC in the FI study were analyzed in these 
patients.  Forty nine patients met these criteria and were analyzed as a separate cohort.  
However, no significant association was identified between FIs and VS in these patients 
(Table 6).  Thus, the variation in VLs in these patients during their participation in the FI 
study appeared to be independent of the FIs. 
 
Table 6: Sample number, contingency table, and results of the statistical analysis of the effects of FIs on 
VL in patients with more than 0 cards, but less than 100% of eligible cards. 
Patients with more than 0 cards, but less than 100% of eligible cards 
 
Baseline 12 Months 18 Months 24 Months IC 
≤400 c/mL 29 23 18 2 23 
>400 c/mL 20 23 17 3 26 
Totals 49 46 35 5 49 
      
 
Chi Square Value p-value OR 95% CL 
12 Months 0.8077 0.4136 0.6897 0.3063 1.5527 
18 Months 0.4982 0.511 0.7302 0.3047 1.75 
24 Months 0.6829 0.6404 0.4598 0.0703 3.0062 
IC 1.4749 0.3115 0.6101 0.2742 1.3572 
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 In order to determine whether specific patient behaviors in terms of care and 
general approach towards the FI were uniquely affected by the FI, the effects of FIs were 
analyzed stratified based on various general characteristics at 12 months, 18 months, 24 
months, and IC of the FI study.  Those characteristics included the following: length of 
participation in the FI study, number of cards qualified for (number of eligible VLs ≤400 
copies/mL), number of cards received, whether the guardian signed for receipt of the FI, 
whether the FIs were picked up before the patient’s next appointment, and the percent of 
qualified cards received.  All of these variables appeared to be unrelated to whether 
patients had VLs below threshold compared to baseline at all time points observed.   
Interestingly, the number of FIs a patient was eligible for and the probability that 
he/she was not virally suppressed after 12 months (p= 0.002), 18 months (p= 0.0043), 
and IC of the FI study (0.0004) was statistically significant.  It is important to remember 
that due to the quarterly visit restriction, only VL measurements ≥3 months from the last 
VL measurement that qualified for a FI were eligible for a FI.  If those eligible VLs were 
<400 copies/mL, then they qualified the patient for a FI.  We observed that the more FIs a 
patient was eligible for, the more likely he/she was to have a VL >400 copies/mL.  For 
example, being eligible for 1 more FI while participating in the FI study made the patient 
2.9 times (95% CL: 1.473- 5.664) more likely to have a VL >400 copies/mL at 12 
months of being eligible for FIs.  This result was also significant at 18 months and IC of 
the FI study (OR at 18 months: 3.643; 95% CL: 1.498- 8.858.  OR at IC: 4.085; 95% CL: 
1.865- 8.946). 
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 A significant association was also found between the percent of eligible cards a 
patient qualified for and VS at 12 months, 18 months, and IC of the FI study.  It was seen 
that a 1% increase in the number of cards a patient qualified for resulted in a >99.9% 
reduction in the chance of not being VS at 12 months, 18 months, and IC of the FI study.  
This largely confirmed our model, as qualifying for cards was the result of being VS. 
 Thus, though 130 patients in this study received at least 1 FI, FIs did not have a 
significant effect on VS regardless of age, gender, PR, and patient behavior. 
 
Survey Study 
 Characteristics of survey respondents.   Exit study experience surveys were 
offered to all guardians and disclosed patients >12 years of age.  Of the 156 patients on 
the TLC-Plus FI study, 120 were approached.  Thirty one patients were not approached 
for the survey arm, because they did not return to the SIS clinic within 6 months of 
completing the FI study.  Five families were excluded, because of language barriers. 
 Among the 120 patients approached, 64 patients >12 years of age were eligible to 
participate in the survey due to their disclosure status.  Of these 64 eligible patients, 62 
agreed, and 2 patients refused due to a lack of interest.  Among the 120 guardians of 
eligible pediatric patients, 28 guardians were not approached.  This was due to the fact 
that their children sought care by themselves, or came to clinic with someone other than 
their legal guardian.  Seven guardians refused to participate in the survey: 3 guardians did 
not feel comfortable enough with English to participate, 3 guardians were not interested 
in participating, and 1 guardian was not familiar with the FI study, because the other 
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guardian tended to the patient’s care on most visits.  A total of 85 guardians participated 
in the survey arm.  Of the 120 families approached to participate, only 1 family (patient 
and guardian pair) refused.  Thus, as seen in Table 7, 147 total surveys were collected, 
which represented 119 families participating in the survey arm.   
 
Table 7: Total number of survey respondents by patient, guardian, and family.  Mean ages and proportions 
of patients in each age cohort of families participating in the survey.  “Patient age of guardian only” 
represents patients of guardian only respondents.  “Total gaurdians” represents PoGs. 
Total # of Survey Participants 
Total surveys 147 
Total patients respondents 62 
Total guardian respondents 85 
Total families responding 119 
 
Total patients n/a 
Patients ≤5 
years old 
Patients 5 to 
13 years old 
Patients >13 
years old Total 
mean age (s.d.) 13.25 (± 4.49) 9 (8%) 53 (44%) 57 (48%) 119 
Patients w/ parent 
survey n/a ≤5 years old 
5 to 13 years 
old 
>13 years 
old Total 
mean age (s.d.) 15.57 (± 2.35) 0 (0%) 6 (21%) 22 (79%) 28 
Patients w/o 
parent survey n/a ≤5 years old 
5 to 13 years 
old 
>13 years 
old Total 
mean age (s.d.) 17.41 (±2.16) 0 (0%) 4 (12%) 30 (88%) 34 
Patient age of 
guardian only n/a ≤5 years old 
5 to 13 years 
old 
>13 years 
old Total 
mean age (s.d.) 9.63 (±3.31) 9 (16%) 42 (75%) 5 (9%) 56 
Total guardians n/a ≤5 years old 
5 to 13 years 
old 
>13 years 
old Total 
mean age (s.d.) 48.14 (±11.65) 9 (11%) 57 (67%) 19 (22%) 85 
 
 Survey participants were grouped into 3 categories: all patients whose family 
participated in the survey (PFPs), all guardian respondents, and all survey respondents.  
PFPs included patients who participated in the survey, and patients whose guardians 
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participated in the survey (PoGs).  All survey respondents included all patient and 
guardian respondents. 
The majority of guardian respondents were female (n= 69; 81%).  One third (n= 
46; 31%) of respondents were from Washington D.C., half were from Maryland (n= 78; 
53%), and a small proportion were from Virginia (n= 23; 16%).  Proportions for PFPs 
were not significantly different from proportions from all patients on the TLC-Plus FI 
study. 
 
 Survey results.  Survey results were grouped into patient, guardian, and total (all 
patient and guardian) responses.  More than half (n= 91, 61%) of all respondents stated 
that it was not hard for the patient to take his/her medications (guardians: n= 51, 60%; 
patients: n= 40, 64.5%).  Conversely, the percent of all respondents that reported taking 
all ARV medications in the week prior was quite high at 71% (n= 105).  This closely 
mirrored the actual proportion of all patients with a VL ≤400 copies/mL at IC of the FI 
study.    The highest overall self-reported barriers were: forgetting (all responses: n=24, 
16.3%), disliking the taste (all responses: n= 25, 17%), and a disliking taking medicine 
(n= 20, 13.6%).  Disliking the taste and taking the medications were the top 2 guardian 
reported barriers to adherence (n= 14, 16.5% and n= 9, 12.9%, respectively).  However, 
adolescent patients reported a slightly different set of barriers.  Forgetting (n= 14, 22.6%) 
and disliking taking the medication (n= 9, 17.7%) were closely followed up by pharmacy 
related barriers (n= 9, 17.7%) and interference of ART with their lifestyles (n= 9, 17.7%). 
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 When asked about responsibility for taking the medications as prescribed, 41.2% 
(n= 35) of guardians reported being responsible for remembering and giving medication 
to their children, and 23.5% of guardians reported that the children were responsible for 
both tasks.  The majority (n= 40, 64.5%) of adolescent patients, however, reported being 
responsible for remember and taking medications themselves and only a small proportion 
of them (n= 5, 8.1%) reported having their guardian remind and give them the 
medications.  It is important to highlight that the guardians represented the younger 
cohort of patients in the study. 
 Various questions in the survey sought to understand satisfaction with the study 
participation and the self-perceived effects of FIs on ART adherence.  The majority of all 
respondents (n= 100, 68.1%) felt that FIs were appropriate to help HIV patients have 
good VLs.  The majority (n= 101, 68.1%) of all respondents also felt similarly about 
using FIs for chronic patients.  More than half (n= 51, 60%) of guardians believed that 
FIs encouraged the parents to give their children their medications.  Similarly, 67% of 
guardians reported that the FI encouraged their children to take their medications.  The 
majority (n= 43, 69.4%) of adolescent patients reported that the FIs encouraged them to 
take their medications.  In terms of the projected long-term outcomes of the FIs, 76.9% 
(n= 113) of all respondents reported planning on taking medication the same way as they 
were during the incentive period.  Only 4% (n= 6) of all respondents reported that no 
longer receiving incentives would adversely affect their adherence.  Finally, 80% of 
guardians (n= 68) reported that their involvement would stay the same as during the FI 
period.  Thus, FIs were largely perceived to be effective in helping with ART adherence 
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by guardians and adolescent patients, and effects were reported to continue despite 
discontinuation of incentives. 
 FIs were also reported to help patients and guardians be more informed of VLs.  
Almost half (n= 73, 49.7%) of all respondents strongly agreed or agreed that FIs helped 
them keep track of laboratory values.  Most importantly, 54.9% of patients (n= 34) 
reported that FIs helped them to keep better track of their laboratory values.  Thus, FI 
were perceived as effective in helping increase patient awareness of their laboratory 
results. 
 Data were also collected on how satisfied patients and guardians were to 
participate in the FI study.  A large majority of all respondents reported being satisfied 
with participating in the FI study (n= 131, 89.1%).  The majority (n= 103, 70.1%) of all 
respondents liked receiving a FI for taking ART.  Furthermore, 78.9% (n= 116) of all 
respondents were extremely or very satisfied to get a FI when the patient’s VL ≤400 
copies/mL.  Interestingly, not receiving a FI did not elicit a negative response of equal 
magnitude.  Only 21.8% (n= 32) of all respondents reported being dissatisfied when the 
patient did not receive a FI for having a VL >400 copies/mL.  Thus, participation in the 
FI study was viewed favorably; however, missing out on the incentive did not elicit a 
negative response in the majority of respondents. 
 In terms of the logistics of participating in the FI study, a majority of all 
respondents reported being satisfied with the process of picking up the FIs (n= 116, 
78.9%).  In fact, 68% (n= 100) of total respondents did not think changes to the FI 
distribution process were necessary.  However, one third of guardians and patients (n= 
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24, 28.2%; n= 17, 27, respectively) would have preferred to have their FIs mailed to 
them. 
 Interestingly, there was a divergence in responses in terms of who decided what to 
do with the FI, and how much of the FI was used by the guardian and patient.  In terms of 
the decision making, 40% of guardians (n= 34) reported splitting the decision with their 
child, while 34.1% of guardians (n= 29) reporting that the children solely decided how 
the FI was used.  Conversely, 74.2% of adolescent patients (n= 46) reported that the 
guardian decided how the FI was used.  In terms of how the FI was distributed between 
guardian and patient, 38.8% of guardians (n= 33) reported that their children used the 
whole FI.  Only 17.6% of guardians (n= 15) reported that the FI was split between the 
guardian and his/her child.  However, 69.4% of adolescent patients (n= 43) reported that 
guardians used the whole FI. 
 The most reported use of the FI from both guardians and patients was clothing 
and shoes (n= 44, 51.8%; n= 37, 59.7%, respectively).  The next three top uses of the FIs, 
as reported by the guardians were toys (n= 29, 34.1%), groceries (n= 29, 34.1%), and 
school supplies (n= 24, 28.2%).  For adolescent patient responses, in addition to clothes 
and shoes, a large proportion of patients reported using the FIs on electronics (n= 23, 
37.1%) and groceries (n= 19, 30.6%).  Interestingly, the FIs were not widely reported to 
be used on classic facilitators of adherence and medical care such as transportation 
(guardians: n= 11, 12.9%; patients: n= 10, 16.1%) and medical expenses (guardians: n= 
3, 3.5%; patients: n= 1, 1.6%). 
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 The final category of responses in which data was collected was whether the 
amount and type of FI was perceived to be appropriate.  The majority of all respondents 
said that $70 was the right amount for the FI (n= 79, 53.4%).  The next most popular 
amount suggested among all respondents was $100 (n= 37, 25.3%).  In terms of whether 
a gift card was the most appropriate type of disbursement, preferences of gift cards were 
compared to cash, store specific gift cards, and gifts.  The neutral stance was the most 
common response regarding whether the respondent preferred cash to the gift card (n= 
43, 29.3%).  Though this was the most common overall answer, adolescent patient 
responses tended to favor cash over the gift card, with 46.8% (n= 29) of them strongly 
agreeing or agreeing that a cash incentive would have been preferred.  The majority (n= 
93, 63.3%) of respondents strongly disagreed or disagreed that a store specific gift card of 
equal magnitude would have been preferred.   Similarly, 74.8% of all respondents (n= 
110) did not want a gift of equal magnitude in place of the FI.  Thus, except for cash, it 
can be seen that the $70 Visa gift card used as the FI was strongly preferred over other 
options.
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Table 8: Selected responses to survey questions.  Responses were viewed in 3 groupings of responses: total responses (n= 147), 
guardian responses (n=85), and patient responses (n= 62). 
I was satisfied with participating in this study in which my 
child was eligible to receive a $70 gift card if my child's viral 
load was below 400 copies 
The FI encouraged me to give my child his/her medications 
or to remind my child to take his/her medications 
Q1 Total Guardian Patient Q2 Total Guardian Patient 
Strongly Agree 
109 
(74.1%) 68 (80%) 41 (66.1%) Strongly Agree 39 (45.9%) 39 (45.9%) N/A 
Agree 22 (15%) 10 (11.8%) 12 (19.4%) Agree 12 (14.1%) 12 (14.1%) N/A 
Neutral 4 (2.7%) 1 (1.2%) 3 (4.8%) Neutral 12 (14.1%) 12 (14.1%) N/A 
Disagree 1 (0.7%) 0 (0%) 1 (1.6%) Disagree 5 (5.9%) 5 (5.9%) N/A 
Strongly 
Disagree 6 (4.1%) 4 (4.7%) 2 (3.2%) 
Strongly 
Disagree 14 (16.5%) 14 (16.5%) N/A 
N/A 5 (34%) 2 (2.4%) 3 (4.8%) N/A 3 (3.5%) 3 (3.5%) N/A 
        The FI encouraged my child to take his/her medications My child's viral load improved because of the FI 
Q3 Total Guardian Patient Q4 Total Guardian Patient 
Strongly Agree 70 (47.6%) 41 (48.2%) 29 (46.8%) Strongly Agree 33 (22.4%) 17 (20%) 16 (25.8%) 
Agree 30 (20.4%) 16 (18.8%) 14 (22.6%) Agree 31 (21.1%) 20 (23.5%) 11 (17.7%) 
Neutral 21 (14.3%) 8 (9.4%) 13 (21.0%) Neutral 38 (25.9%) 17 (20%) 21 (33.9%) 
Disagree 9 (6.1%) 7 (8.2%) 2 (3.2%) Disagree 22 (15.0%) 12 (14.1%) 10 (33.9%) 
Strongly 
Disagree 11 (7.5%) 10 (11.8%) 1 (1.6%) 
Strongly 
Disagree 17 (11.6%) 16 (18.8%) 1 (1.6%) 
N/A 6 (4.1%) 3 (3.5%) 3 (4.8%) N/A 6 (4.1%) 3 (3.5%) 3 (4.8%) 
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I liked receiving the FI as an incentive for giving my child 
his/her medications or for reminding my child to take 
his/her medications 
The FI helped me to be more informed in following my 
child's treatment results. 
Q5 Total Guardian Patient Q6 Total Guardian Patient 
Strongly 
Agree 78 (53.1%) 40 (47.1%) 38 (61.3%) 
Strongly 
Agree 46 (31.3%) 26 (30.6%) 20 (32.3%) 
Agree 25 (17.0%) 12 (14.1%) 13 (21%) Agree 27 (18.4%) 13 (15.3%) 14 (22.6%) 
Neutral 20 (13.6%) 15 (17.6%) 5 (8.1%) Neutral 39 (26.5%) 18 (21.2%) 21 (33.9%) 
Disagree 5 (3.4%) 5 (5.9% 0 (0%) Disagree 16 (10.9%) 11 (12.9%) 5 (8.1%) 
Strongly 
Disagree 8 (5.4%) 7 (8.2%) 1 (1.6%) 
Strongly 
Disagree 11 (7.5%) 11 (12.9%) 0 (0%) 
N/A 1 (0.7%) 0 (0%) 1 (1.6%) N/A 8 (5.4%) 6 (7.1%) 2 (3.2%) 
DNR 10 (6.8%) 6 (7.1%) 4 (6.5%) 
    How did you feel when your child received a FI because 
his/her viral load was below 400 copies? 
How did you feel when your child did not receive a FI 
because his/her viral load was above 400 copies? 
Q7 Total Guardian Patient Q8 Total Guardian Patient 
Extremely 
Satisfied 91 (61.9%) 57 (67.1%) 34 (54.8%) 
Extremely 
Satisfied 7 (4.8%) 7 (8.2%) 0 (0%) 
Very 
Satisfied 25 (17%) 10 (11.8%) 15 (24.2%) 
Very 
Satisfied 10 (6.8%) 9 (10.6%) 1 (1.6%) 
Satisfied 14 (9.5%) 8 (9.4%) 6 (9.7%) Satisfied 21 (14.3%) 11 (12.9%) 10 (16.1%) 
Somewhat 
Satisfied 1 (0.7%) 1 (1.2%) 0 (0%) 
Somewhat 
Satisfied 9 (6.1%) 4 (4.7%) 5 (8.1%) 
Unsatisfied 3 (2%) 1 (1.2%) 2 (3.2%) Unsatisfied 32 (21.8%) 14 (16.5%) 18 (29%) 
N/A 13 (8.8%) 8 (9.4%) 5 (8%) N/A 68 (46.3%) 40 (47.1%) 28 (45.2%) 
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Responsibility for taking medication 
Q19 Total Guardian Patient 
Child is responsible for both remembering time and administering 60 (40.8%) 20 (23.5%) 40 (64.5%) 
Guardian is responsible for both remembering and administering 40 (27.2%) 35 (41.2%) 5 (8.1%) 
Child is responsible for remembering and guardian is responsible for 
administering 13 (8.8%) 8 (9.4%) 5 (8.1%) 
Guardian is responsible for remember and child is responsible for 
administering 26 (17.7%) 17 (20%) 9 (14.5%) 
Other 8 (5.4%) 5 (5.9%) 3 (4.8%) 
 
It is difficult for the patient to take his/her medications Barriers to medication adherence: 
Q20 Total Guardian Patient Q21 Total Guardian Patient 
Strongly 
agree 10 (6.8%) 7 (8.2%) 3 (4.8%) Pharmacy issues 16 (10.9%) 5 (5.9%) 11 (17.7%) 
Agree 10 (6.8%) 8 (9.4%) 2 (3.2%) 
Guardian forgets to 
refill 12 (8.2%) 5 (5.9%) 7 (11.3%) 
Neutral 31 (21.1%) 15 (17.6%) 16 (25.8%) Distaste 25 (17%) 14 (16.5%) 11 (17.7%) 
Disagree 32 (21.8%) 18 (21.2%) 14 (22.6%) Amount is too much 13 (8.8%) 8 (9.4%) 5 (8.1%) 
Strongly 
disagree 59 (40.1%) 33 (38.8%) 26 (41.9%) Forget 24 (16.3%) 10 (11.8%) 14 (22.6%) 
N/A 3 (2%) 2 (2.4%) 1 (1.6%) Side effects 8 (5.4%) 2 (2.4%) 6 (9.7%) 
DNR 2 (1.4%) 2 (2.4%) 0 (0%) 
Interferes with 
lifestyle 14 (9.5%) 3 (3.5%) 11 (17.7%) 
    
Does not like to take 
medications 20 (13.6%) 11 (12.9%) 9 (14.5%) 
    
Other 16 (10.9%) 11 (12.9%) 5 (8.1%) 
 
 
 
  
 
3
9
 
 
 
 
 
 
In the past week, my child has taken his/her medications: How will not receiving FIs affect medication adherence? 
Q22 Total Guardian Patient Q23 Total Guardian Patient 
All of the time 
105 
(71.4%) 
61 
(71.8%) 44 (71%) 
Less likely to take 
medications 6 (4.1%) 0 (0%) 6 (9.7%) 
Most of the time 
29 
(19.7%) 
14 
(16.5%) 15 (24.2%) 
Continue the same 
as now 
113 
(76.9%) 
67 
(78.8%) 46 (74.2%) 
Some of the time 8 (5.4%) 6 (7.1%) 2 (3.2%) 
More likely to take 
medication 
15 
(10.2%) 9 (10.6%) 6 (9.7%) 
None of the time 4 (2.7%) 3 (3.5%) 1 (1.6%) N/A 12 (8.2%) 8 (9.4%) 4 (6.5%) 
N/A 1 (0.7%) 1 (1.2%) 0 (0%) DNR 1 (0.7%) 1 (1.2%) 0 (0%) 
How will not receiving FIs affect guardian involvement 
I believe that FIs given for taking medications and having 
good treatment results are appropriate for patients with HIV 
Q24 Total Guardian Patient Q25 Total Guardian Patient 
Less likely to 
remind child 1 (1.2%) 1 (1.2%) N/A Strongly agree 
58 
(39.5%) 
37 
(43.5%) 21 (33.9%) 
Involvement will 
stay the same 68 (80%) 68 (80%) N/A Agree 
42 
(28.6%) 
22 
(25.9%) 20 (32.3%) 
More likely to 
remind child 6 (7.1%) 6 (7.1%) N/A Neutral 
34 
(23.1%) 
16 
(18.8%) 18 (29%) 
N/A 8 (9.4%) 8 (9.4%) N/A Disagree 7 (4.8%) 6 (7.1%) 1 (1.6%) 
DNR 2 (2.4%) 2 (2.4%) N/A Strongly disagree 4 (2.7%) 2 (2.4%) 2 (3.2%) 
    N/A 2 (1.4%) 2 (2.4%) 0 (0%) 
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Table 9:  Survey responses that were significantly correlated to changes in VL throughout the FI study.  A multinomial multivariate 
logistic regression was used to identify significant survey responses.  VLs at baseline were compared to VLs at 12 months and IC of 
participation in the FI study.  Levels of outcomes included “gets worse” (VL went over threshold after participation), “improves” 
(VL went under threshold after participation), “no change” (VL didn’t cross threshold after FI study participation), and “late” 
(patients completing participation or dropping out before 12 months).  (n)-Target gives the number of responses that meet the 
response and comparison characteristic.  (n)-No change gives the number of respondents who did not change VL throughout the 
course of the FI study. 
Response Baseline 
to: 
Comparing p-value OR 95% CL (n)- 
Target 
(n)- No 
change 
I was very satisfied when my child did not 
receive a FI because his/her VL was above 
400 c/mL 
12 months Late vs. No 
change 
0.048 7.33 1.018 52.84 10 112 
I was satisfied when my child did not 
receive a FI because his/her VL was above 
400 c/mL 
12 months Late vs. No 
change 
0.0301 5.87 1.19 29.014 10 112 
I was unsatisfied when my child did not 
receive a FI because his/her VL was above 
400 c/mL 
12 months Gets worse vs. No 
change 
0.0007 11 2.76 43.89 16 112 
IC Gets worse vs. No 
change 
0.001 15.08 3.01 75.53 14 118 
I strongly agree that I would have 
preferred to receive a gift worth $70 
instead of the $70 gift card 
12 months Improves vs. No 
change 
0.0085 33 2.44 446.08 6 67 
IC Improves vs. No 
change 
0.0151 23.33 1.84 296.19 8 71 
The FI was used on transportation IC Improves vs. No 
change 
0.0405 5.72 1.078 30.33 8 71 
I was satisfied with the process of picking 
up the FI and do not think any changes are 
needed 
IC Gets worse vs. No 
change 
0.037 0.096 0.011 0.87 6 71 
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 Correlations between survey answers and the effects of FIs.  Finally, a 
multinomial multivariate logistic regression was performed to identify possible 
subpopulations of patients that were uniquely affected by FIs.  This regression compared 
whether survey responses were significantly associated with a change in VL from 
baseline to 12 months or IC of participation in the FI study.  However, it is important to 
note that the outcome used was whether VLs crossed the threshold of 400 copies/mL.  As 
a result, an improvement in VL that did not go below 400 copies/mL was not considered 
an improvement by this analysis.  Thus, when patients are referred to as having VLs that 
“became worse” in the following, it strictly implies that VLs went from <400 copies/mL 
at baseline to >400 copies/mL by the indicated time point.  The converse applies to VLs 
that “improved” or “became better.”  Survey responses that were significantly associated 
with changes in VL after participation in FIs are listed in table 9.   
Those patients who reported using the FI for transportation were 5.72 times more 
likely to have a VL that improved from baseline to IC of participation in the FI study.  
Conversely, responding that the FI was used on medical expenses, another common 
barrier to treatment adherence, was not significantly associated with a change in VL. 
 There were 3 responses identified by the regression related to satisfaction with 
receiving the FI for having a specific trend in VL.  Those who responded that they were 
either very satisfied or satisfied when they did not receive a FI for having a VL >400 
copies/mL were significantly more likely to complete participation in the FI study before 
12 months (7.33; 95% CL: 1.018- 52.84 and 5.87; 95% CL: 1.19- 29.01 times more 
likely, respectively).  Those who reported that they were unsatisfied when they did not 
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receive a FI for having a VL >400 copies/mL were significantly more likely to have VLs 
that were worse at 12 months and IC of participation in the FI study (11 times; 95% CL: 
2.76- 43.89 and 15 times; 95% CL: 3.01- 75.53 more likely, respectively). 
 Responses specifically related to the promotion of personal responsibility were 
also closely evaluated.  Those included responses related to whether the FIs encouraged 
the patient and guardian to improve mediation adherence; whether the FIs were picked up 
early; whether the patient signed for the FI; and whether the FI helped the family keep 
better track of laboratory results.  None of these survey responses related to the 
promotion of personal responsibility were significantly associated with an improvement 
in VL after participation in the FI study. 
 Finally, 2 responses related to the logistics of the FI study were significantly 
associated with changes in VL after participation in the FI study.  First, those who 
reported that a $70 gift was preferable to the $70 gift card were significantly more likely 
to see an improvement in VL after participation in the FI study.  At 12 months, those who 
submitted that response were 33 times (95% CL: 2.44- 446.08) more likely to see an 
improvement in VL relative to no change in VL.  At IC of participation in the FI study, 
those who submitted that response were 23.33 (95% CL: 1.84- 296.19) times more likely 
to see an improvement in VL relative to no change in VL.  Second, those who reported 
that they were satisfied with the FI pick-up process used were 90.4% less likely (OR: 
0.096; 95% CL: 0.011- 0.87) to have a VL that got worse during participation in the FI 
study, relative to those who had a VL that did not change.  
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DISCUSSION 
 
Financial Incentive Arm 
 The first aim of this study evaluated the effect of FIs on VS in pediatric HIV-
infected patients.  We hypothesized that FIs would have a measurable effect on the VS of 
pediatric HIV patients for several reasons.  First, the promotion of personal responsibility 
and self-efficacy associated with FIs59,60, could help children assume a larger role in their 
ART administration as they mature 81, especially since a strong correlation has been 
reported between self-efficacy and mediation adherence82.  Adherence interventions 
focusing on self-efficacy have been equally reported to be effective in pediatric HIV 
patients83.  Second, providing cell phones to youth with HIV, which represents a possible 
incentive structure, has been demonstrated to help them improve their ART adherence 
and biologic disease outcomes56.  Finally, FIs have also been reported to have a 
significant effect on adherence to ART in adult HIV-infected patients with a history of 
injection drug use75–77. 
Our data did not reveal a significant association between receiving FIs and VS 
after 12 months, 18 months, 24 months, and IC of being eligible, qualifying and receiving 
FIs for VS.  This result was consistent whether the study population was stratified by age, 
gender, and PR.  In fact, under the assumption that FIs may not help patients who had 
VLs consistently >400 copies/mL or ≤400 copies/mL, a theoretical target subpopulation 
was created for the data analysis.  This cohort included all patients who received more 
than 1 FI, but less than 100% of FIs they were eligible for.  Because the VLs of these 
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patients fluctuated during the course of the study, we hypothesized that we may be able to 
see a trend towards VLs ≤400 copies/mL while participating in the FI study.  
Unfortunately, even within this stratification, no significant association was observed 
between participation in the FI study and VLs ≤400 copies/mL.  
 We did observe two associations between general gift card statistics, FIs, and 
VLs.  First, the data showed that patients who qualified for 1% more of eligible FIs were 
>99% less likely to have a VL >400 copies/mL at 12 months, 18 months, and IC of 
participation in the FI study.  This association was not seen at 24 months of participation 
in the FI study, but this is likely due to the fact that the sample size at that time point was 
too small.  This result was largely expected, as qualifying for a FI required a VL ≤400 
copies/mL. 
 Second, the data had demonstrated that being eligible for 1 more FI made it 
approximately 3 times more likely that a patient had a VL >400 copies/mL at 12 months, 
18 months, and IC of participation in the FI study.  This observation is likely due to the 
fact that patients who are less adherent have generally worse health, and might visit the 
clinic more frequently.  In fact, this is consistent with published data on the association 
between poor adherence, worse health, and increased hospital visits84.  In addition to this 
effect, it is very likely that patients with good adherence space out their clinic visits more, 
as they are confident in their health, while patients with poor adherence are brought more 
frequently to the appointments for closer control and adherence interventions in clinic, 
which is the standard of practice at SIS. 
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 There are various alternative interpretations to the FI’s lack of effect on VS.  First, 
it is possible that FIs did not have an effect due to the usage of VL as an indirect metric 
of adherence.  Like with the aforementioned FI studies in adult HIV patients 75–77, it is 
possible that FIs did improve adherence, but these improvements did not carry over to 
virologic outcomes, like suppressed VLs.  In fact, 71.4% of PFPs reported taking their 
medications all of the time in the past week, which was an improvement to the 24% of 
patients from the CNMC SIS clinic at a different time point 34, and in line with other 
published rates of pediatric adherence85.  Unfortunately, it is not clear whether this is an 
improvement in adherence due to FIs, or an overall improvement of adherence in the 
population over time.  This is supported by the evidence that approximately 70% of PFPs 
had ≤400 copies/mL at baseline and at IC of participation in the FI study.  Though there 
was a self-reported improvement in adherence over time, this was more likely due to a 
change in the patient and caregiver drug taking routines and may not have been related to 
the effect of the FIs. 
 Another possible reason FIs were not associated with VS is the duration of the 
study.  FIs have been suggested to be most effective for short-term changes and in 
patients with more acute conditions29.   Our study was conducted over a 24 month period, 
and outcomes were measured at 12 months, 18 months, 24 months, and IC of 
participation in the FI study (mean of 17.5 months).  As a result, we could speculate that 
these time points are outside of the timeframe during which FIs might be effective.  
However, this is unlikely as initial analysis of the effects of FIs on VLs at earlier time 
points showed that the number of patients VS decreased by the end of 12 months of 
 46 
 
participation in the FI study.  This was largely driven by the decrease in proportion of 
males who achieved VS.  Therefore, the lack of observed effect of FIs on VS is likely not 
a consequence of the timeframe during which FIs were administered. 
 Another possible reason why FIs did not have an observable effect in VS invokes 
multicomponent interventions.  It has been reported that the majority of multicomponent 
interventions were very effective in improving adherence to ART regimens in HIV 
patients41.  The most effective multicomponent interventions included individualized 
education, adherence tools, and a system to address common adherence barriers.  
Interestingly, all of these services are available to the SIS patients and their caregivers 
through the support services supported by the Ryan White funding.  Thus, it is possible 
that FIs were not seen to have an effect on VLs in pediatric HIV patients, because they 
were not a significant improvement over the enhanced adherence support system in place.  
This hypothesis also opens up the possibility that the upper limit or natural rate of perfect 
adherence is 70%.  In fact, rates of adherence 85, and rates of VL suppression 53 are 
commonly reported in this range.  Unfortunately, in order to identify their true effects, 
FIs may need to be compared to no treatment, which is unlikely given the myriad of 
ethical implications involved and potential harm to subjects. 
 Finally, it is important to note that a possible reason why FIs were not observed to 
influence VLs in pediatric HIV patients is due to the overall study design.  As previously 
noted, this study had a prospective cohort design, because it was a component of a larger 
nationwide site-randomized trial.  Site-randomization was used to prevent alienation of 
patients under care at a clinic.  Though a thorough analysis was performed, the study 
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design didn’t allow us to conclusively rule out unidentified confounding factors and carry 
out a comparison with a non-FI pediatric practice.  The only way to address this issue is 
with a control group to compare the FI intervention against.  Thus, future studies will 
need to include a site-randomized pediatric practice control group in order to make 
definitive conclusions about the effects of FIs on adherence in pediatric HIV patients.  
Nonetheless, initial results from our study suggest that FIs are not effective in helping 
pediatric HIV patients overcome the dynamic barriers to their adherence. 
 
Post-incentive patient/ guardian survey 
 The main goals of the post-incentive survey study were to collect information on 
the self-perceived effects of FIs, satisfaction with participation in the study, and to gain 
insight into the self-perceived effects of the FIs on adherence in pediatric HIV-infected 
patients.  The results of the post-incentive survey will be discussed by the themes in 
which the questions were addressed to the patients and their caregivers: 
 Self-perceived effects of FIs.  Overall, the self-reported effects of FIs were very 
positive.  The majority of guardians and adolescent patients reported that FIs helped them 
in their adherence to ART, and that these effects would last even after the incentive 
period was over.  This is important because positive effects of FIs have often been 
reported to fade after incentive periods64–66.  Despite these positive reports, no significant 
associations between changes in VL after participation in the FI study and these survey 
responses were seen. 
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 Interestingly, the respondents also generally reported that virologic outcomes 
improved due to FIs, which was not the case.  
 A majority of patients also believed that FIs helped them keep track of their 
laboratory results.  While the knowledge of laboratory results has been reported to 
correlate with improved virologic outcomes 83, it has not been confirmed in our study. 
 When discussing the self-perceived effects of FIs, it is also important to mention 
the emotional effects of FIs on patients and their families.  The majority of respondents 
who received at least 1 FI reported being extremely or very satisfied to receive the FI 
when the patient’s VL was ≤400 copies/mL.  Interestingly, not receiving a FI for a VL 
>400 copies/mL did not elicit a negative response of equal magnitude, with less than a 
quarter of respondents reporting being unsatisfied for not receiving a FI due to an 
elevated VL. 
 Despite the lack of a significant association between level of satisfaction and 
receiving a card, those who submitted the non sequitur answer of being extremely 
satisfied or very satisfied when the patient did not receive a FI because of elevated VL 
were significantly more likely to complete participation in the FI study within the first 12 
months of participation. 
The respondents who were unsatisfied when they did not receive a FI, because of 
a lack of VS, were significantly more likely to have a VL that got worse over the course 
of the study.  This is a surprising finding, since one might expect that being unsatisfied 
with the VL results would motivate the respondents to do better and spur changes to 
improve adherence.  Importantly, the fact that the negative response was correctly 
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associated with the poor outcome indicates that the respondents knew that the patient’s 
VLs were getting worse. 
 This finding represents 2 interesting possibilities.  The first is that the patients 
and/or their guardians knew that their VLs were getting worse, but could not stop this 
deterioration.  This is largely consistent with the fact that barriers to adherence in 
pediatric patients can be some of the most dynamic and difficult to address 41.  Due to the 
effectiveness of modern ART, these patients may represent those who can be helped by 
increased utilization of support services.  However, due to the already extensive support 
services provided at the SIS clinic, this possibility is less likely to resolve the issue. 
 The other possibility is that poor laboratory results, and the subsequent missed 
opportunities to correct them, caused a negative emotional reaction in the patient and/or 
guardian that was counterproductive to the patient’s adherence.  Thus, participation in the 
FI program and the inability to receive the FI could actually produce a negative response 
in these patients.  In fact, this idea is consistent with published literature on emotional 
disposition, outlook, and treatment adherence 86,87.  Negative outlooks and emotional 
dispositions tended to correlate with worse adherence, while the converse also held true.  
This is important, because it suggest those who tend to have negative outlooks may be a 
population in which FIs do more harm than good. Future studies are needed to better 
evaluate the association between adherence interventions and patient emotional 
responses. 
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 Overall, the self-perceived effects of FIs were largely positive, despite the fact 
that no significant association was seen between these positive responses and actual 
laboratory values in the study of the effects of FIs on VS.  
 Satisfaction with participation in the FI study.  Survey questions also collected 
data on satisfaction with participation in the FI study.  These data were important to 
assess whether any logistical details were possible confounders, and where the incentive 
structure could have been improved.  This part of the survey included questions on the 
appropriateness of FIs, the disbursement process, the amount, and the type of FI used. 
 First, it was seen that the majority of patients and guardians thought that FIs were 
appropriate for patients with HIV and chronic illnesses.  Interestingly, there were more 
respondents who felt that FIs were appropriate for patients with chronic illnesses than 
those who felt that FIs were appropriate for patients with HIV.  This is interesting, 
because it would be expected that patients identify more with their own disease than 
another.  We can speculate that the patients’ experiences with living with HIV allow 
them to understand and empathize with the challenges of living with other chronic 
illnesses. 
 This possibility of empathy is important, since public opinion towards FIs as an 
adherence intervention has been previously reported to be largely negative in several 
studies88,89.  However, it is important to notice that in these studies the majority of those 
with an unfavorable opinion of FIs did not fully understand the incentive structures or 
goals.  Conversely, those who had an understanding of these issues took a more neutral 
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and positive stance towards FIs as an adherence intervention, demonstrating that 
improved education is an important component in the acceptance and usage of FIs. 
 The majority of participants liked getting a FI as an incentive for improving 
medication adherence.  Though this result can be viewed as an inevitable consequence of 
receiving money, this is likely not the case.  Under this assumption, respondents should 
have reported that the appropriate amount of money for a FI be greater than what was 
offered.  However, the majority of respondents believed that the correct amount of money 
was the $70 offered.  Thus, it can be seen that the majority of respondents recognized the 
FI as an adherence intervention, and enjoyed participating in the intervention. 
 The majority of respondents also reported being satisfied with the study design, 
and that it did not need to be changed.  Interestingly, this response was associated with a 
change in VL in these participants.  Respondents who were satisfied with the study 
design were significantly less likely to have an increase in their VL.  Since changes in VL 
were defined as crossing the 400 copies/mL threshold, it was observed that FIs had a 
protective stabilizing effect on VLs in patients who were already VS.  The role of the FIs 
as a means of maintenance of suppressed VLs is novel and deserves further investigation. 
 Though the majority of survey respondents did not think that anything in the 
study needed to be changed, almost one-third of respondents (28%) wanted the FI to be 
mailed to them.  However, this suggestion would be difficult to implement properly, as 
mailing the FI has a strong potential to decrease the salience of the purpose of the 
incentive.  This is largely due to the fact that disbursement of the FI through the mail is a 
largely passive act, while the pickup process used in the study was an active one.  Adding 
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a mailing option to the study disbursement process would decrease opportunities to 
discuss laboratory results and changes with clinicians and support staff.  Thus, it can be 
seen that though many respondents were interested in receiving their FIs by mail, this 
may actually be counterproductive. 
 Finally, data were collected on the preferences of the type of FI used in the study.  
Alternatives compared cash, a store specific gift card, and a gift to the $70 Visa gift card 
distributed in this study.  The majority of respondents were against store specific gift 
cards and gifts.  When comparing cash to the Visa gift card, the responses were generally 
neutral, with almost all responses garnering at least 10% of respondents.  However, when 
focused on patient responses, it was clear that patients tended to favor cash.  This is likely 
reflective of the fact that cash has more utility for young people, who are less inclined to 
be familiar and comfortable with using a Visa gift card.  Nonetheless, the aforementioned 
results are consistent with published results that unconstrained incentives are generally 
more valuable to patients than incentives with restrictions, such as store specific gift 
cards. 
 Interestingly, though those strongly preferring a $70 gift to the $70 FI constituted 
the minority, these patients were among those who had a significant correlation of FIs 
with an improvement in VL.  Published data have suggested that a gift is one of the least 
valuable incentives to a patient due to its lack of utility 90.  Since FIs use objects of value 
to evoke changes in behavior, one would expect incentives relatively more valuable to the 
patient to produce greater degrees of change.  While it is possible that gifts represented a 
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more valuable incentive to this cohort of patients in our study patients, this result is more 
likely due to a difference in personal responsibility. 
   Prior research has shown that the magnitude of the incentive value is not as 
important as how effectively the message is being spread to the patient 62.  Though cash 
or a gift card may be relatively more valuable to a patient, it is possible that a gift may 
more effectively evoke the idea of an incentive for medication adherence.  Thus, in terms 
of those who responded that they would have preferred a gift, it is also possible that these 
patients grasped the idea of an incentive for medication adherence more effectively and 
therefore tended to have better virologic outcomes while participating in the FI study. 
 
 Personal responsibility and barriers to adherence.  The post-incentive survey 
also collected information on personal responsibility and barriers to adherence in the 
patients.  The collection of these data was aimed to address a lack of data for the 
development of a stronger theoretical foundation to address medication adherence in 
pediatric patients35. 
 In our study we considered picking up the FIs early after the VS result a 
characteristic of enhanced personal responsibility, because it required the family to pay 
close attention to the laboratory results and make an extra trip to the clinic.  We 
hypothesized that those who responded that they picked up cards early would have an 
improvement in VLs while on FIs.  However, early pickup of the FI did not correlate with 
VS in our study.  It is likely that those who promote personal responsibility practiced 
these behaviors before participating in the FI study, and therefore, this response was not 
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associated with an improvement in VL because these patients were already virologically 
suppressed. 
 Finally, it is important to discuss the responses which reflected how the spending 
of the FIs was distributed between guardian and pediatric and adolescent patients.  The 
majority of guardians reported that children decided and used most or the whole FI.  On 
the contrary, adolescent patients reported that guardians decided and used the whole card.  
Taking into consideration that patients surveyed were >12 years of age, we speculate that 
patients who responded largely exercised more autonomy in spending the FIs due to their 
age.  Due to the ethical and developmental considerations, we were unable to capture the 
opinion of the younger patients and only collected data from the guardians for the 
younger subjects in the study. 
While it may be impossible to determine the actual distribution of decision and 
usage between all pediatric patients and their guardians, these results are important 
because they suggest a limitation in the post-incentive study.  Since both groups reported 
that the FIs were largely used by the other party, it can be seen that patients did not feel 
rewarded for improving their ART adherence, nor did guardians feel rewarded for 
working with younger patients, refilling prescriptions, or dispensing each dose.  While 
incentives directed generally at  guardians 72 or patients 91 were seen to be effective, there 
are currently no studies investigating the distribution of the incentives between guardians 
and patients.  This difference in distribution among the users and suppliers/providers in 
our study may serve as an explanation why FIs were not significantly associated with a 
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change in VL in actual patients. Future studies may need to address the direct incentive 
assignment to children, adolescents, and their guardians. 
Interestingly, reported utilization of the FIs was helpful in identifying barriers to 
adherence.  The two most popular uses of the FI were clothing and groceries.  However, 
both of these responses were not significantly associated with a change in VL.  
Conversely, those who reported using the FI for transportation were 23 to 33 times more 
likely to improve their VL during the study.  Since transportation is a commonly reported 
facilitator of medication adherence86, this finding may indicate the use of FIs in 
facilitating adherence. 
For overall barriers to adherence, there are two important survey responses related 
to the self-reported barriers.  Interestingly, 10.9% of respondents reported that pharmacy 
issues were a significant barrier to their/their children’s adherence.  However, a previous 
study showed that pharmacy issues were not significantly associated with poor adherence 
in a closely related cohort34.  Thus, this result likely represents another example of the 
aforementioned disconnect between self-perceived effects and actual laboratory values.  
Moreover, none of the self-reported barriers—such as pharmacy issues, guardians 
forgetting to refill, dislike of the medication’s taste, having too many medications, 
forgetting to take the medications, medication side effects, interference with lifestyle, and 
disliking the taking of medicine—was associated with a change in virological outcome. 
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Conclusions and Future Directions 
 In conclusion, in our study FIs were not associated with achieving VS in a cohort 
of pediatric and adolescent patients with HIV infections.  The study, however, identified 
significant self-perceived benefits of FIs on adherence among adolescent patients and 
guardians of all pediatric and adolescent patients in the study.   
Future studies with separate targets of FIs (patients and guardians) could help 
identify the most effective mechanism for promoting personal responsibility.  The 
investigation of the relationship between emotional responses and success with 
medication adherence interventions should also be investigated.  This is especially 
relevant to those patients who had a strong negative response to not qualifying for the FI 
and were much more likely to have worse virological outcomes while participating in the 
FI study.  Most importantly, a strong education component should be included in future 
studies to maximize the benefits of receiving FIs.  
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